OpenAI's former research chief raising $70M for startup - WSJ

OpenAI's former research chief raising $70M for startup - WSJ

OpenAI Alum Launches Biotech Startup with $130M Raise at $1.3B Valuation

Chai Discovery, a San Francisco-based biotech startup co-founded by Joshua Meier—a former executive at OpenAI and Meta AI—has secured $130 million in new funding at a $1.3 billion valuation, bringing its total capital raised to $225 million. The round, led by Oak HC/FT and General Catalyst, with participation from Thrive Capital and Menlo Ventures, will advance the company's AI-driven drug discovery platform.

Chai Discovery aims to revolutionize molecular design by leveraging computational tools to tackle diseases traditionally resistant to conventional therapies. Its flagship technology, Chai-2, enables the de novo design of antibodies targeting complex pathogens and cancer-related proteins. Early results indicate a 20% success rate in generating viable antibody candidates, a significant improvement over traditional methods, which typically yield less than 0.1% efficacy.

The startup's leadership team combines expertise in AI, biotechnology, and large-scale engineering. CEO Meier previously contributed to AI initiatives at OpenAI and Absci, while co-founder Jack Dent brings operational experience from Stripe. The board includes Mikael Dolsten, former chief scientific officer at Pfizer, who has overseen the development of 36 approved medicines.

Chai's approach shifts from predictive modeling to generative design, allowing researchers to create novel molecular structures without relying on existing templates. This strategy targets "undruggable" disease mechanisms, including viral proteins and oncology pathways, potentially reducing the time and cost of drug development.

Investors highlight the growing role of AI in biotech. "It can take over a decade and cost upwards of a billion dollars to bring a medicine from bench to bedside," said Annie Lamont of Oak HC/FT. "Chai Discovery is rewriting that story." With its latest funding, the company now faces the challenge of translating computational breakthroughs into clinically viable therapies.

The biotech sector's increasing reliance on AI-driven innovation underscores the broader trend of technology reshaping pharmaceutical R&D. As Chai advances its pipeline, its success could signal a shift in how treatments are conceptualized and developed.